Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-P39
- Development stage
- Approved
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
CT-P39 is a biosimilar of omalizumab, developed by Celltrion. It is a humanized monoclonal antibody that targets immunoglobulin E (IgE), acting as an IgE receptor antagonist. By binding to free IgE, it prevents the interaction of IgE with its high-affinity receptor (FcεRI) on the surface of mast cells and basophils, thereby inhibiting the allergic inflammatory cascade. CT-P39 has demonstrated equivalent efficacy and safety to reference omalizumab in clinical trials for chronic spontaneous urticaria and other allergic conditions[1][2][3]. It is approved for use in asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), IgE-mediated food allergy, and chronic spontaneous urticaria[5].
- Brand names
- Omlyclo
- Other names
- omalizumab-igecomalizumab biosimilar-CelltrionXolair biosimilar-Celltrion
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on CT-P39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-P39.